NCT05510674View on ClinicalTrials.gov

Safety and Dose Ranging Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution)

PHASE1CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

September 20, 2023

Study Completion Date

September 20, 2023

Conditions

Lung Cancer

Interventions

DIAGNOSTIC_TEST

OWL-EVO1

EVOC probe

Trial Locations (2)

CB20AY

Royal Papworth Hospital NHS Foundation Trust, Cambridge

M239QZ

Wythenshawe Hospital, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Owlstone Ltd

INDUSTRY